ACCG-2671 — Initial data
Q3 2026
Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026Source filing
GPCR biotech catalysts & pipeline
STRUCTURE THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
aleniglipron — Topline data
Q3 2026
Topline 72-week aleniglipron ACCESS OLE data on track for Q3 2026;Source filing
aleniglipron — Topline data
Q4 2026
data from body composition, type 2 diabetes/obesity and SWITCH clinical trials on track for Q4 2026Source filing